STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
As of 31 March 2016, the total number of shares in Recipharm AB (publ) (“Recipharm”) amounts to 49,614,980 shares, divided into 12,685,716 shares of series A, 36,429,264 shares of series B and 500,000 shares of series D. The total number of votes in Recipharm as of 31 March 2016 amounts to 163,786,424.
The number of shares and votes in Recipharm has increased as a result of the issue of 1,039,724 shares of series B directed to certain sellers of Mitim S.r.l., as announced by Recipharm on 23 February 2016.
This information is published in accordance with Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act (SFS 1991:980). This information was submitted for publication on 31 March 2016, at 08:00 am CET.
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,700 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.4 billion and the Company operates development and manufacturing facilities in France, Germany, Italy, Israel, Portugal, Spain, Sweden and the UK and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03
This information was brought to you by Cision http://news.cision.com